Article

Global Alpha Insights: investing in resilience beyond political cycles

January 2025 / 3 minutes

The US election, with Donald Trump's re-election, dominated markets this month. Amy Dinwoodie, investment specialist, explains why we believe elections don't impact stock market returns and why your Global Alpha portfolio remains well-positioned regardless of who sits in the presidential seat.

© Shutterstock / Orhan Cam

As with any investment, your capital is at risk

We start by reminding our readers that since the inception of Global Alpha in 2005, during which we’ve seen four presidents, we have not repositioned our portfolios or made any knee-jerk reactions with regard to who is in the White House. We firmly believe that innovation and entrepreneurship drive markets over and above politics. Instead, we remain focused on finding companies that we believe can grow at above-market rates for above-market duration. 

That said however, we have considered some of the moving parts that markets could experience with a second Trump presidency. US stocks surged initially, and expectations are that the administration and/or policies will look very similar to those of his first term - tax cuts, deregulation and tariffs. With the Republicans also having won the Senate and the House, there is potentially more ability for Trump to drive policy change more effectively.

One of the structural trends that our Global Alpha Team believes hosts a plethora of long-term opportunities is the revitalisation and enhancement of infrastructure in the States. Decades-old electrical grids, roads, railways and internet providers are no longer fit to cope with today’s modern technology and population needs.

Indeed, America’s infrastructure lags many other developed economies including China. The American Society of Civil Engineers estimates an infrastructure investment gap of nearly $2.6trn this decade. We believe that spending in this area will continue regardless of who occupies the presidential suite. Building aggregate businesses such as Martin Marietta and CRH will benefit from this required spend.

Energy seems likely to be in focus too. We have exposure to companies electrifying energy generation and storage, such as Eaton. We think costs ultimately dictate choices, and the drivers for ongoing electrification of energy generation and storage will persist. As solar deployments spread, the US could benefit from extremely low-cost electricity generation, particularly in the sunbelt. Eaton’s electrical power management systems seem set to be in demand.

Another area that’s been a hot topic for our clients is how further tariffs could impact companies held in the portfolio. The first point we’d note is that we’ve been through something akin to this in Trump’s first presidency. As such, many companies have already adapted their supply chains to rely less on foreign manufacturers or suppliers. Recent conflicts in the Middle East and Europe have also likely driven companies to move quickly in this area.

If we were to zoom in on just the Chinese companies in the portfolio - where we have minimal direct exposure, ~3.5% across four names - our investment activity in this region has been more focused on investing in domestic winners than those that rely on exports. For example, electric vehicle manufacturer Li Auto generates 100 per cent of sales from the Chinese market, and the e-commerce platform Pinduoduo - while operating an international arm through Temu - still generates the majority of revenues from Chinese consumers. We therefore believe the portfolio is well-insulated from any shocks in this area. 

And finally, the appointment of RFK Junior has been an interesting move - perhaps flagging more questions than answers around the future of the healthcare sector. RFK wants the FDA to be tougher on big pharma. At the same time, another member of the ‘governmental efficiency’ department - Ramaswamy - has argued that the FDA is too restrictive, creating barriers to innovation. Ramaswamy made his fortune investing in biotech. This leads to an imbalanced view of US healthcare. In the near term, we don’t expect any drastic changes in healthcare, largely because existing reforms are hard to undo, e.g. if any limits were placed on Medicare’s coverage of GLP-1s (medicines used to treat type 2 diabetes), the public could react very strongly. But we must take a step back and remember that presidents don’t affect long-term share price appreciation. If you look at the share price of Novo Nordisk from 2000 to 2024 - a period that has seen five different presidents, it has moved from 9DK to around 750DK today.

Ultimately, while we can and do seek out particular dependencies in our analysis, we control best for this by selecting stocks that we think can grow across a wide range of backdrops because of the attractiveness of their products and services. We do not have an edge in political analysis, so while stock markets play this game, we focus on long-term growth opportunities. That’s where the largest returns are made. We aim for those returns by investing in businesses where growth will outlast political cycles and then holding them through the inevitable ups and downs.

 


Global Alpha (including Global Alpha, Responsible Global Alpha, Global Alpha Paris Aligned and Responsible Global Alpha Paris Aligned strategies)

Annual past performance to 31 December each year (net%)

 

2020

2021

2022

2023

2024

Global Alpha Composite

36.4 7.3 -29.1 19.5 11.1

MSCI ACWI Index

16.8 19.0 -18.0 22.8 18.0

 

Annualised returns to 31 December 2024 (net%)

 

1 year

5 years

10 years

Global Alpha Composite

11.1 6.6 9.0

MSCI ACWI Index

18.0 10.6 9.8

Source: Revolution, MSCI. US dollars. Returns have been calculated by reducing the gross return by the highest annual management fee for the composite. 1 year figures are not annualised.

Past performance is not a guide to future returns.

Legal notice: MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Risk factors

The views expressed should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

This communication was produced and approved in January 2025 and has not been updated subsequently. It represents views held at the time of writing and may not reflect current thinking.

Potential for profit and loss

All investment strategies have the potential for profit and loss, your or your clients’ capital may be at risk. Past performance is not a guide to future returns.

This communication contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act (‘FinSA’) and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated.

The images used in this communication are for illustrative purposes only.

 

Important information 

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

Financial intermediaries

This communication is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

Europe

Baillie Gifford Investment Management (Europe) Ltd (BGE) is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. BGE also has regulatory permissions to perform Individual Portfolio Management activities. BGE provides investment management and advisory services to European (excluding UK) segregated clients. BGE has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc. BGE is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited and Baillie Gifford & Co are authorised and regulated in the UK by the Financial Conduct Authority.

Hong Kong

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 license from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong. Telephone +852 3756 5700.

South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

Japan

Mitsubishi UFJ Baillie Gifford Asset Management Limited (‘MUBGAM’) is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited. MUBGAM is authorised and regulated by the Financial Conduct Authority.

Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a “wholesale client” within the meaning of section 761G of the Corporations Act 2001 (Cth) (“Corporations Act”).  Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client.  In no circumstances may this material be made available to a “retail client” within the meaning of section 761G of the Corporations Act.

This material contains general information only.  It does not take into account any person’s objectives, financial situation or needs.

South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission (‘OSC’). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited (‘BGE’) relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

Israel

Baillie Gifford Overseas Limited is not licensed under Israel’s Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755–1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This material is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

Singapore

Baillie Gifford Asia (Singapore) Private Limited is wholly owned by Baillie Gifford Overseas Limited and is regulated by the Monetary Authority of Singapore as a holder of a capital markets services licence to conduct fund management activities for institutional investors and accredited investors in Singapore. Baillie Gifford Overseas Limited, as a foreign related corporation of Baillie Gifford Asia (Singapore) Private Limited, has entered into a cross-border business arrangement with Baillie Gifford Asia (Singapore) Private Limited, and shall be relying upon the exemption under regulation 4 of the Securities and Futures (Exemption for Cross-Border Arrangements) (Foreign Related Corporations) Regulations 2021 which enables both Baillie Gifford Overseas Limited and Baillie Gifford Asia (Singapore) Private Limited to market the full range of segregated mandate services to institutional investors and accredited investors in Singapore.

 

129628 10052185

About the author